Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec:101:191-193.
doi: 10.1016/j.ijid.2020.09.1451. Epub 2020 Sep 28.

Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia

Álvaro A Faccini-Martínez  1 , Ricardo Rivero  2 , Evelin Garay  2 , Alejandra García  2 , Salim Mattar  3 , Yesica Botero  2 , Ketty Galeano  2 , Jorge Miranda  2 , Caty Martínez  2 , Camilo Guzmán  2 , Germán Arrieta  1 , Hector Contreras  2 , Hugo Kerguelen  4 , Maria Moscote  5 , Eimi Brango  6 , Veronica Contreras  2
Affiliations

Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia

Álvaro A Faccini-Martínez et al. Int J Infect Dis. 2020 Dec.

Abstract

Objectives: We investigated seroreactivity by using a commercial SARS-CoV-2 ELISA test in samples collected from different groups of individuals, including patients diagnosed to have Dengue, Zika, and Chikungunya infection between 2015 and 2019, from an endemic area in the Caribbean Colombian region.

Methods: A total of 127 sera samples obtained from six different groups of individuals were included in this study: Group A: patients with confirmed SARS-CoV-2 infection; Group B: patients with symptoms suggestive of COVID-19 or asymptomatic contacts with confirmed patients; Group C: patients with acute or recent dengue virus infection; Group D: patients with acute Zika virus infection; Group E: patients with previous Chikungunya virus infection; and Group F: individuals with exposure to spotted fever group rickettsiae.

Results: Overall, group A, group B, and group D showed seroreactivity to SARS-CoV-2 in 92%, 75%, and 26% of samples, respectively; furthermore, group C, group E, and group F showed 100% seronegativity.

Conclusions: We found 26% of serological cross-reactivity in patients with acute Zika virus infection by using a commercial SARS-CoV-2 ELISA test. Further studies are needed to evaluate whether serological cross-reaction is maintained with time in nonacute patients with previous exposure to the Zika virus and its effect in SARS-CoV-2 serosurveys in endemic areas for this arbovirus.

Keywords: Arbovirus infection; Diagnosis; Endemic diseases; Validation study.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. https://coronavirus.jhu.edu/map.html. [cited 2020 Sept 21].
    1. Arrieta G., Mattar S., Villero-Wolf Y. Evaluation of serological test of Zika in an endemic area of flavivirus in the Colombian Caribbean. Ann Clin Microbiol Antimicrob. 2019;18(1):29. - PMC - PubMed
    1. Chams N., Chams S., Badran R. COVID-19: a multidisciplinary review. Front Public Health. 2020;8:383. - PMC - PubMed
    1. Hanson K.E., Caliendo A.M., Arias C.A. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19:serologic testing. Clin Infect Dis. 2020 ciaa1343. - PMC - PubMed
    1. Lustig Y., Keler S., Kolodny R. Potential antigenic cross-reactivity between SARS-CoV-2 and Dengue viruses. Clin Infect Dis. 2020 ciaa1207. - PMC - PubMed

MeSH terms

Substances